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Small Molecule Inhibited 
Parathyroid Hormone Mediated 
cAMP Response by N–Terminal 
Peptide Binding
Amit Kumar1,2, Monika Baumann2 & Jochen Balbach2,3
Ligand binding to certain classes of G protein coupled receptors (GPCRs) stimulates the rapid synthesis 
of cAMP through G protein. Human parathyroid hormone (PTH), a member of class B GPCRs, binds to its 
receptor via its N–terminal domain, thereby activating the pathway to this secondary messenger inside 
cells. Presently, GPCRs are the target of many pharmaceuticals however, these drugs target only a small 
fraction of structurally known GPCRs (about 10%). Coordination complexes are gaining interest due 
to their wide applications in the medicinal field. In the present studies we explored the potential of a 
coordination complex of Zn(II) and anthracenyl–terpyridine as a modulator of the parathyroid hormone 
response. Preferential interactions at the N–terminal domain of the peptide hormone were manifested 
by suppressed cAMP generation inside the cells. These observations contribute a regulatory component 
to the current GPCR–cAMP paradigm, where not the receptor itself, but the activating hormone is 
a target. To our knowledge, this is the first report about a coordination complex modulating GPCR 
activity at the level of deactivating its agonist. Developing such molecules might help in the control of 
pathogenic PTH function such as  hyperparathyroidism, where control of excess hormonal activity is 
essentially required.
Usage of mixed–ligand complexes is a rapidly growing area due to their applications in the industrial, environ-
mental and medicinal fields1. Their applications range from anticancer2–5 to antimicrobial3,4,6,7 and antifungal 
activities3,4,8. For the normal function of biochemical pathways in organisms transition metal ions are essential 
components. Therefore, it is not surprising that coordination complexes are of great interest. These complexes 
exhibit versatile spectral and electrochemical properties with tunable coordination chemistry, which subse-
quently offer an enormous scope for the design of new species. Complexes of various metal ions are under intense 
investigation to highlight their potential in medicinal chemistry9–11. Zn is one of the most common metal ions 
found in biological systems12,13, e.g. playing an important role in many transcription factors. Diverse biological 
functions of Zn(II) result from its redox stability and variability in coordination chemistry. Zn based coordination 
compounds are gaining interest because they show better biological responses towards infectious organisms than 
free metals2,5–8. For instance, Zn complexes have been studied to induce phosphorylation of the Akt downstream 
effector glycogen synthase kinase 3β and attributed useful tools for regulating glucose metabolism or serve as 
lead structures for developing antidiabetic drugs14. Other studies showed the inhibition of caspase-3 activity and 
promotion of ErbB1-ErbB2 heterodimerization by Zinc pyrithione15 and inhibition of cyclin-dependent kinase 
CDK116. Other examples include Zn complexes exhibiting the antibacterial/antimicrobial, anticancer activities, 
interacting with the DNA and inducing protein aggregation2,5–8,17.
At present, cell surface receptors including GPCRs have been frequently targeted by potential drug mole-
cules for pharmacological applications18–21. GPCRs form the largest family of human transmembrane proteins 
and play a major role in various physiological functions, including cell–cell communication, cell differentiation, 
metabolism and synaptic transmission. Various signaling molecules including hormones, neurotransmitters, 
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chemokines, ions, tastants and odorants bind to GPCRs22 and activate the pathways to secondary messengers 
such as inositol trisphosphate, diacylglycerol, cGMP or cAMP23–26. Agonists such as PTH, PTH related pep-
tide or tuberoinfundibular peptide of 39 residues (TIP39) interact with parathyroid hormone receptors 1 and 2 
(PTH1R/2R), both members of class B GPCRs, and activate intracellular signaling, in turn modulating cellular 
function, including the skeletal, endocrine, cardiovascular and nervous systems24,27–30. Therefore, PTH(1–34) and 
PTH(1–84) are also used as drugs against osteoporosis31,32.
PTH is secreted by the parathyroid gland as an 84 residue peptide and regulates the calcium and phosphate 
levels in the blood stream. However, in the case of hyperparathyroidism, PTH level become elevated which trig-
gers the excess release of calcium into the bloodstream. This calcium is taken from the bones, which subsequently 
leds to bone fatigue. The elevated levels of calcium may increase in the urine and cause kidney stones. At the 
molecular level, basic signal transduction starts when PTH binds to its receptors leading to their activation and 
subsequent generation of secondary messengers22,24,33. PTH binding and receptor activation is carried out by 
the N–terminal part of the peptide34. It implies that one possible regulation of hormonal activity could be at the 
ligand level, particularly the N–terminal domain of PTH. Recently, it has been reported that N–terminal phos-
phorylation at Ser1, Ser3 and Ser17 of PTH abolished receptor activity24.
As GPCRs are involved in many diseases, they are targets for approximately 40% of all human modern medic-
inal drugs35–36. However, these drugs target only a small fraction (about 10%) of known GPCRs37. Within the con-
text of receptors including GPCRs, typically available drug molecules for pharmacological applications directly 
target the receptors18–21. However, literature is limited with regards to molecules which bind to the agonist to 
modify its receptor activating function. A potential class of molecules for this purpose could be organic/coordi-
nation/mixed–ligand complexes. In mixed–ligand complexes one metal ion can replace another metal ion bear-
ing the original skeletal system. A metal replacement can lead to suppressed or negligible biological responses9. 
Previously we have developed the Cu(II) complex of anthracenyl terpyridine which showed nuclease and anti-
prolifirative activity for a broad range of cancer cells9. In principle, Zn(II) is less toxic than Cu(II) and it is redox 
silent therefore, this metal was chosen in exchange of Cu(II). Moreover, metal insertion is essential as anthracenyl 
terpyridine is water insoluble in the absence of the metal. A replacement of Zn(II) in anthracenyl terpyridine did 
not show nuclease or antiprolifirative activities9.
In the present studies, a mixed–ligand of Zn(II) and anthracenyl terpyridine (Fig. 1)9 has been employed as 
a modulator of the PTH response by directly targeting the agonist. We found that the Zn complex binds PTH 
with micromolar affinity without inducing major conformational changes of the peptide hormone. NMR spec-
troscopy revealed that the Zn complex preferentially binds to the N–terminal domain of PTH which is important 
for receptor binding and activation. We attribute specific hydrophobic interactions between PTH and the Zn 
complex for binding. An intracellular signalling assay revealed that interactions at the N–terminal domain led to 
Figure 1. Line representation of the Zn2+ complex of anthracenyl terpyridine9.
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suppressed secondary messenger cAMP generation in cultured cell. Thus a mixed–ligand metal complex provides 
an additional regulatory component for specific agonist inhibition of GPCR activation.
Results
Binding revealed by fluorescence spectroscopy. The natural form of parathyroid hormone comprises 
84 residues, however, PTH(1–34) is sufficient for receptor activation38. PTH contains one tryptophan residue 
at position 23. Thus it can be used as a highly sensitive fluorescent probe for the analysis of ligand binding by 
fluorescence spectroscopy. PTH is composed of structured sections mainly from positions 1–37, whereas the 
C–terminal part is largely unstructured39,40. When excited at 280 nm, PTH showed the intrinsic fluorescence 
emission maxima centered at 348 nm, which is characteristic of Trp exposed to the solvent, as supported by the 
NMR structure. In order to establish the binding a titration experiment was carried out where the PTH(1–34) 
concentration was kept constant and the concentration of the Zn complex was varied. A non–linear decrease in 
fluorescence intensity was observed with increasing concentration of the Zn complex suggesting quenching of the 
tryptophan fluorescence upon binding of the Zn complex.
The fluorescence quenching behavior was analyzed according to the equation given in the experimental sec-
tion. The data showed the exponential decay as a function of Zn complex (Fig. 2a and Figure S1). Data fitting 
resulted in a KD value as 27 ± 1.8 μM indicating a moderate binding affinity of the Zn complex to PTH(1–34) and 
a stoichiometry of 1.9 (numbers of binding sites with equal affinities). In order to evaluate the interaction at the 
C–terminal part of the PTH and its role in binding, full length PTH(1–84) was taken and its binding was estab-
lished. Similar to the PTH(1–34), PTH(1–84) also showed the quenching in fluorescence intensity as a function 
of the Zn complex concentration. This resulted in a KD value of 34 ± 1.7 μM and a stoichiometry of 2.0. Thus, the 
Zn complex showed almost the same affinity towards PTH(1–34) and PTH(1–84) and both peptide hormones 
interact with two molecules of Zn complex. Zn–perchlorate up to 200 μM did not show any significant change 
in fluorescence intensity (Figure S1). In a second control experiment, 9-anthracenemethanol was titrated against 
PTH(1–84) which showed a significantly weak affinity (KD = 3.52 ± 0.38 mM) compared to the Zn complex 
(Figure S2). This highlights the crucial role of the organic skeletal together with metal ion for efficient binding 
beyond an unspecific hydrophobic interaction.
A closer analysis of the fluorescence data suggested that there is negligible difference in the quenching behav-
ior of PTH(1–34) and PTH(1–84). Data were further analyzed based upon the relative intensity plot (Fig. 2a). The 
plot of PTH(1–84) suggests ~75% reduced intensity at the end of the titration (76 μM of Zn complex), it was ~86% 
in the case of PTH(1–34) at the same concentration. This behavior can be further understood from the concentra-
tions of the Zn complex required for 50% quenching of fluorescence intensity (CF50)41. The CF50 for PTH(1–34) 
was 21.46 ± 0.5 μM and for PTH(1–84) it was 31.8 ± 0.8 μM (Fig. 2b). These analyses confirm that the Zn complex 
binds to PTH(1–34) and PTH(1–84) in a similar way, although there are trivial differences in the interactions.
Binding revealed by CD spectroscopy. Possible conformational changes of peptide secondary struc-
ture induced in PTH(1–34) or PTH(1–84) upon binding the Zn complex can be revealed by circular dichroism 
(CD) spectroscopy. The CD spectrum of PTH(1–34)42 and PTH(1–84)43 showed minima at 222 nm, character-
istic of α –helical content. A pronounced minimum at 202 nm is attributed towards unstructured regions at the 
C – terminus of the peptide which is dominating the far UV CD spectrum. The binding of the Zn complex to the 
PTH(1–34) or PTH(1–84) did not show significant changes in the CD spectra and thus no secondary structural 
changes of the peptides (Fig. 3a and Figure S3).
Thermodynamics of binding by ITC studies. ITC is a well suited method to evaluate protein-ligand 
interaction41,44. The interaction of the Zn complex with PTH(1–34) and PTH(1–84) was evaluated by ITC at 
25 °C. Zn complex binding was exothermic in nature for both the peptides (Fig. 3b and Figure S4). Data fitting 
gave n values of 2.28 ± 0.13 and 1.93 ± 0.04 for PTH(1–34) and PTH(1–84), respectively. This is suggestive of 
at least two molecules of the Zn complex interacting with the peptides. The isotherm yields the following ther-
modynamic parameters: (KD = 55.06 ± 0.06 μM, ∆ H = − 5.9 ± 0.1 kcal mol−1and ∆ S = − 5.37 cal mol−1K−1) and 
Figure 2. Fluorescence quenching of the PTH peptide hormone by the Zn complex. (a) Relative fluorescence 
intensity plot and best fit (red lines) according to equation for ■ – PTH(1–34) and  – PTH(1–84). (b) CF50 in 
μM (concentrations of the Zn complex required for 50% fluorescence quenching) plot.
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(KD = 54.1 ± 0.08 μM, ∆ H − 11.25 ± 0.3 kcal mol−1 and ∆ S = − 7.15 cal mol−1K−1) for PTH(1–34) and PTH(1–84), 
respectively. The dissociation constant in the low micromolar range and negative ∆ H indicates that the Zn com-
plex interacts with the peptide hormones via rather weak interactions. The enthalpic gain counterbalances the 
unfavorable loss in entropy of the system upon complex binding.
NMR titration of Zn complex with 15N–PTH(1–34) and 15N–PTH(1–84). NMR spectroscopy is a 
well suited method to investigate the exact binding sites, and conformational and/or dynamic changes upon 
protein–ligand interactions in solution24,45,46. Therefore, NMR titration experiments of 15N–PTH(1–34) and 15N–
PTH(1–84) with the Zn complex were performed. The recorded 15N–HSQC experiment detects only backbone 
amides of 15N–PTH(1–34) or 15N–PTH(1–84) and suppresses all resonances of the Zn complex. A comparison 
of the spectra of 15N–PTH (1–34) in the free (black) and bound state (red) (Fig. 4) revealed differences in the 
chemical shifts and the line width of the resonances of individual residues. Many of the resonances were broad-
ened beyond detection limits, possibly because of medium exchange rates on the NMR chemical shift time scale 
between free and bound PTH. Other residues change their chemical shift values. It is interesting to note that 
almost all residues showed changes in cross peak intensity and/or in chemical shift. This signifies that the whole 
peptide sequence of PTH(1–34) is involved in binding with the Zn complex.
Preferential binding at residue-level resolution was further investigated by choosing full length 15N PTH(1–84) 
to see whether or not the C–terminal region is involved in the Zn complex interaction. A gross analysis showed 
that the Zn complex binds to N–terminal residues (Fig. 5a). At the end of the titration, several residues showed 
decreased NMR intensities. Notably, native resonances of residues V2, Q6, M8, H9, N10, L11, G12, H14, L15, 
N16, E19, W23, L24, R25, Q29, D30, H32, N33, F34, V35 and H63 were almost completely missing upon Zn com-
plex addition. As a control, addition of 200 μM of Zn–perchlorate to PTH(1–84) did not show a significant change 
in NMR cross peaks (Figure S5). These data were quantified by comparing the intensity of each of the individual 
cross peaks of the PTH(1–84)/Zn complex with PTH(1–84) in the absence of the Zn complex (Fig. 5b). These 
NMR spectra indicate that the N–terminal domain of PTH (1–84) binds to the Zn complex whereas the C–termi-
nus part remains solvent exposed and flexible enough to result in observable resonances. It is interesting to note 
that the aromatic residues (W23, F34) and all histidines (H9, H14, H32 and H63) plus their hydrophobic neigh-
bouring residues are the hotspots of NMR intensity loss upon Zn complex addition, suggesting that their side 
chains facilitate binding. Histidine 63 is the only exception in the C–terminal part of PTH(1–84) sensing complex 
formation. In a control NMR titration experiment the interaction of 9-anthracenemethanol with PTH(1–84) 
showed no residue specific NMR intensity loss and thus the signature of an unspecific hydrophobic PTH peptide 
interaction (Figure S6).
The NMR data clearly demonstrated that the Zn complex binds preferably at the N–terminal domain of the 
peptide hormone irrespective of the peptide length. This possibly explained the binding behaviour observed by 
fluorescence spectroscopy and ITC which yielded nearly identical affinity. The additional Zn complex interactions 
Figure 3. Binding analysis of the Zn complex with peptide hormones. (a) CD spectra of PTH(1–34) upon 
titration with the Zn complex (10 μM to 50 μM). The black spectrum corresponds to free PTH(1–34). Spectra 
beyond 215 nm could not be recorded due to the high absorption upon addition of the Zn complex (b) ITC 
profile and best fit of the interaction of Zn complex with PTH(1–34). Top: raw data obtained from injections of 
the Zn complex into the PTH(1–34) solution. Bottom represents the integrated curve showing the experimental 
points (■ ) and best fit (–).
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of V35–A42 and S62–H63 in PTH(1–84) compared to PTH(1–34) have no significant contribution to the 
observed KD values.
Inhibition of cAMP pathway. Fluorescence spectroscopy and ITC revealed the binding of the Zn complex 
with PTH(1–34) and PTH(1–84). NMR spectroscopy identified that the Zn complex interacts with the N–termi-
nal part of the peptide hormone. The binding region from residues 1–37 of PTH(84) is important for recognition, 
interaction with the extracellular loops and trans–membrane helices of the receptor and bringing about activation 
of the later. There are two principal signal transduction pathways involving the G protein–coupled receptors: 
the cAMP signal pathway and the phosphatidylinositol signal pathway47. Parathyroid hormone is involved in 
the cAMP pathway for its biological regulation. Because binding of the Zn complex was at the N–terminal part 
of PTH, it is interesting to investigate the cAMP response towards its receptor in the presence of the Zn com-
plex. Therefore PTH(1–34) and PTH(1–84) induced cAMP accumulation was measured in stable HEK 293 cell 
lines expressing recombinant PTH1R33. A cAMP generation assay was carried out in a Zn complex concentra-
tion dependent manner, keeping the cells and peptide hormone concentrations constant. PTH response without 
Zn complex was considered as 100% cAMP response. The peptide hormones were exposed to Zn complex for 
15 minutes to allow for complex formation and subsequently cAMP generation was studied. A 50% reduced 
activity was observed at 2 μM of Zn complex and complete suppression of the cAMP response was observed at 
~20 μM for both the peptides (Fig. 6). These results confirm that Zn complex binding at the N–terminal domain 
led to inactivation of the peptide hormones.
The cAMP generation was also analyzed to see the effect of the Zn complex on the receptor itself. Here, the 
Zn complex was pre-incubated with the cells followed by addition of PTH(1–84). This experiment did not show a 
significant suppression of cAMP generation inside the cells (black bars in Figure S7). The direct interaction of the 
Zn complex with the isolated N-terminus extracellular domain of PTH receptor 1 (nECD) was further analyzed 
by fluorescence spectroscopy where it showed a significantly weak affinity (KD = 3.05 ± 0.2 mM) (Figure S8). In 
another control experiment cAMP generation was also studied by incubating the 9-anthracenemethanol with the 
peptide (Figure S9) or directly with the cells (grey bars in Figure S7). In both cases a significant suppression of 
intracellular cAMP generation was not observed. Additionally, inhibition of cAMP response or cell toxicity was 
also not observed up to 100 μM of Zn–perchlorate (Figure S10).
Figure 4. Binding of the Zn complex with PTH(1–34) mapped by NMR spectroscopy. Superimposed 2D 
1H–15N HSQC spectra of 15N PTH(1–34) in the free state (black) and bound to the Zn complex (red).
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Discussion
Here we are presenting a detailed analysis of the interaction of the Zn(II) complex of anthracenyl terpyridine 
with the human peptide hormones PTH(1–34) and PTH(1–84) and its modulating response towards their PTH1 
receptors. Fluorescence and ITC studies suggested that at least two molecules of this Zn complex bind at the 
N–terminal domain of PTH. Binding at multiple sites is a common phenomenon for small ligands interacting 
with targeted proteins. For example, NMR spectroscopic analysis showed that two c–Myc–Max complex inhibi-
tors, 10058–F4 and 10074–G5, bound to multiple regions of the monomeric c–Myc bHLHZip domain to inhibit 
the interaction between the binding partners48. Other examples are binding of epigallochatechin gallate (EGCG) 
to polypeptides, including α –synuclein and amyloid Aβ thereby redirecting the systems to nontoxic protein 
aggregates49,50 or EGCG inhibition of PTH(1–84) fibril growth46. Here the naturally secreted mature PTH peptide 
contains 84 residues, PTH(1–84), which is composed of three distinct regions: residues ~1–15 are involved in 
Figure 5. Binding profile of the Zn complex toward the PTH(1–84). (a) 2D 1H–15N HSQC overlaid spectrum 
of 15N PTH(1–84) in the free state (black) and bound to the Zn complex (red). (b) Residue by residue relative 
NMR intensity plot of 15N PTH(1–84) in the bound state with Zn complex compared to free 15N PTH(1–84). 
Residues lost > 80% of intensity are marked red, 50–20% losses are given in cyan and no significant change in 
blue. The structure of PTH(1–84) (structure of residues 1–39, PDB: 1BWX)63 is displayed above the intensity 
plot. No bars are given for the prolines at positions 40, 43 and 51.
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interaction with trans–membrane helices and activation of the receptor51,52, ~15–37 are responsible for receptor 
recognition at its ectodomain53–55, while the function of residues ~37–84 is not clear56. Both the free PTH peptide 
and the receptor bound state show α –helical secondary structure for residues ~1 to 34 (respective PDB codes are 
1ZWB39 and 3C4M)40. The presented NMR data resulted in detected chemical shift changes of residues between 2 
and ~42. The structured elements thus played an important role in interaction with the Zn complex.
All major NMR intensity losses of PTH(1–84) residues upon binding of the Zn complex occur close to the 
N-terminal aromatic and histidine residues of the peptide. Titration with Zn-perchlorate showed that free Zn(II) 
is unable to bind to PTH, thus highlighting that the organic skeletal system plays an important role in interaction. 
We further suggest that this system provides the specific hydrophobic interactions of PTH recognition because 
binding studies with 9-anthracenemethanol showed no preferential binding in the NMR titration experiment and 
only very weak affinity revealed by the fluorescence and ITC experiments.
The NMR detected chemical shift changes were observed at the N–terminal domain of the peptide hormone, 
thereby resulting in a suppressed cAMP response (Fig. 6). The decrease response was also detected by substitu-
tion of PTH residues. The tenth and eleventh residues of parathyroid hormone PTH(1–12) are important for 
stabilizing its helical conformation. The substitution of Leu7 with Phe7, Ala10 with Glu10 and/or the Arg11 with 
Ile11, markedly decreased cAMP generation25. It was also reported that the first, second, fourth, fifth, seventh, 
and eighth residue of PTH as well as W23 and F34, are important components of receptor binding/activation53,57. 
In the present studies these residues showed significant chemical shift changes and are thus expected to have an 
effect on the biological response.
The interaction of small molecules with proteins often occurs along the whole molecule e.g., NMR detected 
binding of EGCG to α –synuclein49, whilst here, the studied Zn complex showed the preferential binding at the 
N–terminal domain of the peptide hormones. Few synthetic molecules for example, 1,3,4–benzotriazepine non–
peptide58 or peptide based DPC–AJ195159 have been identified as parathyroid hormone–1 receptor (PTH1R) 
antagonists. These synthetic molecules act as activator for the receptor, while the present Zn complex acts as the 
inhibitor of an agonist. Mono– and bicyclic analogs of parathyroid hormone–related protein have been prepared 
and structurally characterized in a TFE:water mixture. However, their in vitro characterization (such as the gen-
eration of cAMP) has not been studied60,61.
A possible application of further developing such small molecules could be for combined treatments. In cer-
tain disease cases, such as  hyperparathyroidism, it is necessary to control the function of PTH at the ligand level. 
So far, various treatments are available, e.g. by calcimimetics, bisphosphonates or hormone replacement therapy 
of parathyroid gland, to suppress the hormone secretion. However a continuous treatment has to be avoided due 
to hypercalcemia and hypercalciuria being frequently observed side effects32. Therefore, a combination of con-
trolling the PTH response at the agonist level as presented here, along with suppression of PTH secretion, could 
be advantageous for immediate response and to improve therapeutic applications.
Methods
Protein expression and purification. Human PTH(1–34) and PTH(1–84) were purified as previously 
reported23. The expression plasmids for both the peptide hormones are based on a pET SUMO adapt vector 
containing C–terminal His–tags. Plasmids were transformed into E. coli BL21 codon+ cells. Uniform 15N isotope 
labeling of peptide hormones was achieved using M9 minimal medium supplemented with 15N NH4Cl. Peptide 
hormones were purified from soluble fractions using Ni–NTA affinity chromatography. Fractions containing 
Figure 6. Inhibition of cAMP response by the Zn complex in stable HEK 293 cells expressing PTH1R. 
The Zn complex was incubated with peptide hormones prior to addition of cells. The upper panel shows 
the response from PTH(1–34) and the bottom panel for PTH(1–84). Error bars present the mean of three 
independent experimental runs in triplicate.
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the peptides were cleaved with SUMO protease (1:100 ratio) 50–150 μg/ml62. The cleaved fractions were further 
purified by S–75 gel filtration chromatography.
Fluorescence spectroscopy. Fluorescence titrations were carried out on a JASCO FP6500. The samples 
were excited at 280 nm wavelength and the emission spectra were recorded in the range between 290 nm to 
450 nm. Experiments were carried out in 10 mM BisTris, 300 mM Na2SO4, 0.02% NaN3, pH 7.2 using a 1 cm 
path length quartz cell. The concentration of PTH(1–34), PTH(1–84) and nECD-PTH1R used in the titra-
tion experiments were 7.4 μM, 8.1 μM and 5 μM, respectively. In a typical titration experiment, 4 μM of Zn 
complex or 9-anthracenemethanol was added and spectra were recorded after each addition. Zn complex or 
9-anthracenemethanol in buffer was used as blank titration and these spectral traces were subtracted from the 
main titration. The Zn complex or 9-anthracenemethanol was dissolved in dimethyl sulfoxide and further diluted 
for experiments. The final concentration of DMSO was < 1% in any experiment.
Fluorescence data were analyzed according to the following equation:
= − + + − + + − +Q Q Q P nL K P nL K PnL P mL( ((( ) ( ) 4 )/2 )) (1)max max 1 D 1 D
2
1 1
with P = (P0 / (V0 + L))V0 and L1 = (L0 / (V0 + L))L and Q – fluorescence intensity, P – protein concentration, L – 
ligand concentration, V – volume, n – binding sites and 0 – indicates start point.
CD spectroscopy. CD spectra were recorded at 25 °C on a Jasco–J–810 spectropolarimeter with a scan 
speed of 20 nm/min. The measurements were carried out in 5 mM BisTris buffer at pH 7.2 with 15 μM of peptide. 
Titration experiments were carried out by addition of 10 μM of Zn complex at each time. Each spectrum reported 
is an average of four successive scans. The blank scans under same conditions were subtracted from the main 
spectral data.
ITC experiment. The calorimetric titrations were performed at 25 °C with a MicroCal VPITC isothermal 
titration calorimeter. Small aliquots (7 μl) of the Zn complex were added to a solution of the respective peptide in 
the calorimeter cell. Successive additions were separated by a 300 second interval to allow the resulting peak from 
peptide Zn complex interaction to return to the baseline. All of the studies were carried out in 10 mM BisTris, 
300 mM Na2SO4, pH 7.2.
NMR spectroscopy. The spectra were recorded at the concentration of 50 μM of peptide hormones. 
Subsequently, titration was carried out with the addition of 0.5 μl of 10 mM Zn complex until there was no further 
change in NMR intensity observed. The spectrum corresponding to the 1:4 complex formations was used for the 
analysis. For the 9-anthracenemethanol titration experiment 20 μM of PTH was used. A titration was carried out 
and the 1:4 complex of PTH:9-anthracenemethanol was analyzed in detail. The spectra were corrected for the 
dilution factor. The previously determined NMR assignments of PTH resonances were used24,63,64. The spectra 
were recorded in the 10 mM BisTris, 300 mM Na2SO4, 0.02% NaN3, pH 5.3, with a Bruker 800 MHz Avance III 
spectrometer equipped with a CP–TCI cryoprobe at 25 °C. Spectra were processed using the programs NMRPipe 
and NMR Draw.
cAMP accumulation assay. HEK 293 cells stably expressing hPTH1R were used for the cAMP accumula-
tion assay following the previously reported procedure24,33. The reaction was carried out at 37 °C and fluorescence 
measurements were taken using a VICTOR X4 2030 plate reader (PerkinElmer Life and Analytical Sciences). A 
fixed amount of 0.01 μM peptide hormones and 4 × 103 cells per well were used to monitor the cAMP response. 
The Zn complex or 9-anthracenemethanol was diluted form 0.1 μM to 100 μM and incubated for 15 minutes 
with the peptide hormone before addition of HEK 293 cells. All experiments were performed in triplicate and 
repeated independently three times. The maximum cAMP response were calculated as a percentage of the max-
imal response of PTH(1–34) or PTH(1–84). The effect of Zn complex or 9-anthracenemethanol on receptor was 
evaluated by incubating these with the cells for 15 minutes followed by washing with buffer. These treated cells 
were added to the reaction mixture containing untreated PTH(1–84) as described above.
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